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Background: More than 25% of patients diagnosed with endometrial carcinoma have an invasive primary cancer
accompanied by metastases. Gonadotropin-releasing hormone (GnRH) plays an important role in reproduction. In
mammals, expression of GnRH-II is higher than GnRH-I in reproductive tissues. Here, we examined the effect of a
GnRH-II agonist on the motility of endometrial cancer cells and its mechanism of action in endometrial cancer
therapy.
Methods: Immunoblotting and immunohistochemistry (IHC) were used to determine the expression of the GnRH-I
receptor protein in human endometrial cancer. The activity of MMP-2 in the conditioned medium was determined
by gelatin zymography. Cell motility was assessed by invasion and migration assay. GnRH-I receptor si-RNA was
applied to knockdown GnRH-I receptor.
Results: The GnRH-I receptor was expressed in the endometrial cancer cells. The GnRH-II agonist promoted cell
motility in a dose-dependent manner. The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and
the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125). Cell motility
promoted by GnRH-II agonist was suppressed in cells that were pretreated with U0126 and SP600125. Moreover,
U0126 and SP600125 abolished the GnRH-II agonist-induced activation of MMP-2. The inhibition of MMP-2 with
MMP-2 inhibitor (OA-Hy) suppressed the increase in cell motility in response to the GnRH-II agonist. Enhanced cell
motility mediated by GnRH-II agonist was also suppressed by the knockdown of the endogenous GnRH-I receptor
using siRNA.
Conclusion: Our study indicates that GnRH-II agonist promoted cell motility of endometrial cancer cells through
the GnRH-I receptor via the phosphorylation of ERK1/2 and JNK, and the subsequent, MAPK-dependent activation
of MMP-2. Our findings represent a new concept regarding the mechanism of GnRH-II-induced cell motility in
endometrial cancer cells and suggest the possibility of exploring GnRH-II as a potential therapeutic target for the
treatment of human endometrial cancer.
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Endometrial cancer is one of the most common gy-
necological cancers in the world and accounts for
approximately 50,000 deaths worldwide each year [1].
Patients with tumor confined to the uterus are treated
with surgery and radiotherapy [2-4]. However, more
than 25% of patients diagnosed with endometrial car-
cinoma have an invasive primary cancer accompanied
by metastases. Despite treatment with aggressive che-
motherapeutic regimens, these patients have a 5-year
survival rate of less than 20% [1]. In fact, metastasis
represents the main cause of death for patients with
endometrial cancer, and the battle against this cancer
would greatly benefit from the identification of factors
involved in the metastatic process. Certain cases of
endometrial cancer with a particular morphology, ad-
verse histopathological features or advanced stage are
characterized by aggressive behavior and poor progno-
sis [5]. The molecular pathogenesis of endometrial can-
cer remains poorly understood, resulting in a limited
cure rate in the treatment of advanced cases. Thus, new
therapeutic approaches are needed for advanced or re-
lapsed disease. The hypothalamic peptide GnRH plays
an important role in the maintenance of intrauterine
tissues and the development of endometrial cancer
[6-9]. In mammals, GnRH-II is more widely present in
peripheral tissues than GnRH-I, which suggests that
GnRH-II may have additional functions. GnRH-II has
been shown to have direct antiproliferative effects in
the growth of endometrial cancer cells [10]. These find-
ings raise the possibility that GnRH-II could directly
regulate the tumor progression of endometrial cancer
cells. The role of GnRH-II in endometrial cancer cell
invasion is not known, and the mechanism by which
GnRH-II regulates the invasiveness of endometrial tu-
mors has also not been established. The MAPKs are
considered to be important components of GnRH-
induced signaling pathways in various cell types
[10-12]. We have previously demonstrated that the
anti-proliferative effect of GnRH-II is mediated by the
MAPKs signalings [10,13]. Different mechanisms have
been suggested for MAPK activation through GPCRs
[14,15]. MMPs are largely implicated in promoting
angiogenesis and tumor metastasis [16,17]. Some evi-
dence indicates an expanded role for GnRH in certain
aspects of gynecologic tumor progression, such as me-
tastasis, via the activation of MMPs and the subsequent
increase in cell migration and invasion [18]. In the
present study, we examined the effect of a GnRH-II
agonist on the motility of endometrial cancer cells and
the mechanisms of the action involved. Our results sug-
gest the possibility of exploring GnRH-II as a potential
therapeutic target for the treatment of human endo-
metrial cancer.Results
GnRH-II stimulates migration and invasion of endometrial
cancer cells
In cancer invasion and metastasis, an imbalanced regula-
tion of cell motility and proteolysis appears to be a critical
event [19]. To study whether the expression of the GnRH-I
receptor is associated with the metastasis of endometrial
cancer cells, the effect of GnRH-II on cell migration and in-
vasion was examined. Ishikawa and ECC-1 endometrial
cancer cells, which express functional GnRH-I receptors
[10], were treated with a GnRH-II agonist. The ability of
the cells to migrate was assessed using a Transwell migra-
tion assay. The GnRH-II agonist stimulated the migration
of endometrial cancer cells through the uncoated porous
filter in a dose-dependent manner at concentrations of 1
nM to 1 μM with a maximal effect at 1 μM (Figure 1A).
We also assessed the invasion of the cells in vitro in
response to the GnRH-II agonist stimulus using Transwells
with filters coated with Matrigel. Our results indicated that
the GnRH-II agonist induced endometrial cancer cell inva-
sion in a dose-dependent manner at concentrations of 1
nM to 1 μM with a maximal effect at 1 μM (Figure 1B).
Expression of the GnRH-I receptor (GnRH-IR) in
endometrial cancer
To examine the expression of the GnRH-I receptor,
Ishikawa and ECC-1 endometrial cancer cells were lysed,
and the expression of GnRH-I receptor was examined by
immunoblot analysis. As shown in Figure 2A, the GnRH-I
receptor was detected in Ishikawa and ECC-1 endometrial
cancer cells. Using immunohistochemical analysis, we
confirmed that the GnRH-I receptor was expressed in the
human endometrial cancer tissue samples (Figure 2B).
The GnRH-II-induced cell migration and invasion is
mediated by GnRH-I receptors in endometrial cancer cells
It is assumed that both GnRH-I and GnRH-II exert their
biological effects by binding to a common GnRH-I re-
ceptor [20]. To investigate whether the effects of GnRH-
II on cell migration and invasion were mediated by the
GnRH-I receptor, Ishikawa and ECC-1 endometrial can-
cer cells were transfected with a GnRH-I receptor siRNA
to knockdown the endogenous GnRH-I receptor expres-
sion. The trnasfection efficiency of siRNA in both
Ishikawa and ECC-1 was examined by using fluorescence-
labeling siRNA, si-GLO. As shown in Figure 3A, both cells
were almost transfected after 24 hours si-GLO transfec-
tion. Treatment with 50 nM GnRH-I receptor siRNA
down-regulated GnRH-I receptor expression in Ishikawa
and ECC-1 endometrial cancer cells (Figure 3B). More-
over, knockdown of the endogenous GnRH-I receptor
significantly abolished the GnRH-II-mediated cell mi-
gration (Figure 3C) and abolished the GnRH-II-pro-
moted cell nvasion. Taken together, these results indicate
Figure 1 GnRH-II stimulates endometrial cancer cell migration and invasion. (A) Using the Transwell migration assay, endometrial cancer
cells were seeded. The GnRH-II agonist stimulated the migration of endometrial cancer cells through the uncoated porous filter in a
dose-dependent manner at concentrations of 1 nM to 1 μM with a maximal effect at 1 μM. (B) Endometrial cancer cells were seeded onto a
Matrigel-precoated filter in the Transwell chambers in the presence or absence of increasing concentrations of GnRH-II agonist (1 nM to 1 μM, as
indicated). After 24 (migration) and 48 (invasion) hours of incubation, cells in the upper side of the filter were removed and the migrated or
invaded cells were fixed, stained, and counted. Left, representative pictures. Columns, the mean number of migrated or invaded cells of five fields
of triplicate wells from three independent experiments; bars, SD; *p<0.05, versus control.
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Figure 2 Immunoblot and immunohistochemical analysis of GnRH-I receptor (GnRH-IR) protein expression in endometrial cancer.
(A) GnRH-I receptor levels in Ishikawa and ECC-1 cells were monitored by immunoblot assays. (B) GnRH-I receptor was stained brown in the
second of three columns depicting human endometrial cancer tissue sections. Sections were counterstained with hematoxylin to show the
nuclei in column 1 of three columns depicting human endometrial cancer tissue sections. Sections were stained without the GnRH-I receptor
antibody as a negative control in the third of three columns depicting human endometrial cancer tissue sections. Micrographs were taken
with a 40Χ objective lens. Scale bars represent 20 μm.
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in endometrial cancer cells are mediated by GnRH-I
receptors.
GnRH-II-induced cell migration and invasion are mediated
by ERK1/2 and JNK signaling in endometrial cancer cells
To investigate the molecular mechanism of GnRH-
II-induced cell migration and invasion in endometrial
cancer cells, the activation of ERK1/2 and JNK signaling
were examined with immunoblot analysis. As shown in
Figure 4A, GnRH-II activated ERK1/2 and JNK signaling
in a time-dependent manner. The effects of GnRH-II on
ERK1/2 and JNK signaling activation were abolished by
transfecting the cells with GnRH-IR siRNA but not with
control siRNA (Figure 4B). To further evaluate the roles
of ERK1/2 and JNK signaling in GnRH-II-induced cell
migration and invasion, endometrial cancer cells were
treated with U0126 and SP600125 along with GnRH-II.
As shown in Figure 4C, pretreatment of the cells with
U0126 or SP600125 abolished the GnRH-II-stimulated cellmigration and invasion. These results suggest that GnRH-
II induced the cell migration and invasion of endometrial
cancer cells through the GnRH-I receptor and the activa-
tion of the ERK1/2 and JNK signaling pathways.
Effects of GnRH-II-induced MMP-2 expression on the cell
migration and invasion of endometrial cancer cells
MMP-2 is largely implicated in promoting angiogenesis
and tumor metastasis. To determine whether MMP-2 is in-
volved in GnRH-II-induced cell migration and invasion of
endometrial cancer cells, the cells were treated with GnRH-
II, and the expression of MMP-2 was detected by immuno-
blot analysis. As shown in Figure 5A, treatment with 1 nM
to 1 μM GnRH-II obviously induced MMP-2 expression.
Furthermore, MMP-2 enzymatic activity was measured by
gelatin zymography using conditioned medium from endo-
metrial cancer cells. The gelatin zymography indicated
stronger lytic zones at the molecular masses corresponding
to the pro- and active-forms of MMP-2 (the 72-kDa and
66-kDa forms, respectively) in the conditioned medium
Figure 3 (See legend on next page.)
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Figure 3 Effects of human GnRH-I receptor siRNA (si-GnRH-IR) transfection on endometrial cancer cells. (A) The transfection efficiency of
siRNA in endometrial cancer cells. (B) GnRH-I receptor levels were monitored by immunoblot assays. The endometrial cancer cells were
transfected with human si-GnRH-IR or scrambled siRNA (si-Ctrl) for one day with Lipofectamine RNAiMAX. (C) The effects of si-GnRH-IR
transfection on the GnRH-II-induced cell migration. The cells were transfected with si-GnRH-IR and treated with GnRH-II (1 μM) for 24 h. The cell
motility was assessed with the migration assay. The results are expressed as the mean ± SEM of three independent experiments. (*p<0.05, versus
control; #p<0.05, versus GnRH-II). The effects of si-GnRH-IR transfection on GnRH-II-induced cell invasion. The cells were transfected with si-GnRH
-IR and treated with GnRH-II (1 μM) for 48 h. The cell motility was assessed with the invasion assay. The results are expressed as the mean ± SEM
of three independent experiments. (*p<0.05, versus control; #p<0.05, versus GnRH- II).
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with that from untreated cells (Figure 5B). A more import-
ant observation was that the GnRH-II-induced cell migra-
tion and invasion were abolished in cells pretreated with
the MMP-2 inhibitor, indicating that MMP-2 was critical
for the effects of GnRH-II on the cell migration and inva-
sion of endometrial cancer cells (Figure 5C).
Discussion
The GnRH pathway is important in the hypothalamus-
pituitary-gonadal axis of reproduction [21]. Previous stud-
ies have demonstrated the direct effects of GnRH analogs
in human endometrial cancer cells [22,23]. Furthermore, it
has been demonstrated that GnRH-II has more potent ef-
fects than GnRH-I in extra-pituitary tissues, such as endo-
metrial tumors, suggesting that GnRH-II could be
considered as a possible therapeutic target for endometrial
cancers [22]. Metastasis represents the main cause of
death for patients with endometrial cancer, and the battle
against this cancer would benefit greatly from the identifi-
cation of factors involved in the metastatic process. How-
ever, the underlying molecular mechanisms utilized by
GnRH-II to regulate the cell migration and invasion of
endometrial cancer are not well known. The GnRH-I
receptor is a member of the GPCR family. GPCRs are
characterized by the presence of seven transmembrane
domains and transfer their signals through multiple G
protein subunits, often stimulating multiple signaling
pathways [24]. Direct evidence showing the presence of a
full-length, functional GnRH-II receptor mRNA in human
tissues is insufficient, and the issue of whether the GnRH-
I receptor mediates the effects of both GnRH-I and
GnRH-II remains unresolved. In this study, we report for
the first time that GnRH-II may contribute to the migra-
tion and invasion of endometrial cancer cells by inducing
the expression of MAPK-mediated MMP-2 through the
GnRH-I receptor, providing an insight into the prospect of
developing targeted therapy for endometrial cancer.
In our previous study [10], the expression of GnRH-II
and its effects on cell growth were demonstrated in
endometrial cancer. In the present study, the treatment
of Ishikawa and ECC-1 endometrial cancer cells with
GnRH-II resulted in significant effects on cell migration
and invasion. These findings suggest that GnRH-IIdirectly induces the cell migration and invasion of endo-
metrial cancer cells and provide in vitro confirmation
that GnRH-II induces cell motility in endometrial can-
cer. These findings confirmed the previous studies
[22,23,25-29] suggesting that GnRH-II may mediates the
cell motility and anti-proliferation in gynecologic cancer
cell lines. Therefore, differences in levels of GnRH-I
receptor, GnRH-II receptor and signaling differentially
affect the apoptotic and motile machinery within cell
lines and contribute to the cell type–specific effects of
GnRH analogues on cell growth and motility.
In this study, GnRH-I receptor siRNA was used to
selectively knock down the protein expression of GnRH-
I receptors in Ishikawa and ECC-1 endometrial cancer
cells. Targeting GnRH-I receptors with siRNA abolished
the GnRH-II-induced cell migration and invasion of
endometrial cancer cells, indicating that the effects of
GnRH-II on endometrial cancer cells is dependent upon
GnRH-I receptors. This finding confirmed previous stud-
ies [10,30-32] that suggested that the GnRH-I receptor
may be a common receptor that mediates the effects of
both GnRH-I and GnRH-II in gynecological cancer cells.
In pituitary gonadotrope cells, MAPKs are considered
to be essential in GnRH-induced signaling pathways
[12,33]. MAPKs contribute to signaling pathways that
mediate cellular responses to different extracellular
stimuli and thereby determine the cell’s behavior. In the
present study, we observed that GnRH-II (1 μM)
resulted in the phosphorylation of ERK1/2 and JNK in
Ishikawa endometrial cancer cells, which is compatible
with a previous study performed in COS-7 cells [34].
Moreover, the activation of ERK1/2 and JNK was mark-
edly attenuated by the specific inhibitors U0126 and
SP600125 in Ishikawa endometrial cancer cells. Treat-
ment with U0126 and SP600125 also attenuated the
GnRH-II-induced cell migration and invasion, further in-
dicating that the GnRH-II-induced activation of ERK1/2
and JNK may have an important role in the regulation of
cell motility in Ishikawa endometrial cancer cells. The
present results indicate that the ERK1/2 and JNK path-
ways might play an important role in mediating the motil-
ity effects of GnRH-II in Ishikawa endometrial cancer
cells. Therefore, attempts to manipulate the ERK1/2 and
JNK signaling that mediates the regulation of cell
Figure 4 The effects of ERK1/2 and JNK signaling in endometrial cancer cells. (A) The effects of GnRH-II on ERK1/2 and JNK signaling
activation. The cells were treated with GnRH-II (1 μM) at different time points. The phosphorylated ERK1/2 (p-ERK1/2), and phosphorylated JNK
(p-JNK) levels were analyzed by immunoblot analysis, which indicated increases in the levels of p-ERK1/2 and p-JNK following 5 min of
stimulation. (B) The effects of human si-GnRH-IR transfection on the GnRH-II-induced activation of ERK1/2 and JNK. The activation of ERK1/2
and JNK induced by GnRH-II (GII) was investigated after si-GnRH-IR transfection and showed significant decreases in the levels of p-ERK1/2 and
p-JNK. (C) The effects of U0126 and SP600125 pretreatment on GnRH-II-induced ERK1/2 and JNK activation. Cells were pretreated individually
with 1 μM U0126 or 1 μM SP600125 for 30 min followed by stimulation with 1 μM GnRH-II for 10 min. The control culture was treated with
DMSO as a vehicle control. Pretreatment with 1 μM U0126 and 1 μM SP600125 individually attenuated the effects of GnRH-II on the induction
of cell migration and invasion. (Columns, mean from three independent experiments in three different passages of the cell line; bars, SE.,
*p<0.05, versus control; #p<0.05, versus GnRH-II).
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Figure 5 The effects of GnRH-II on MMP-2 expression in endometrial cancer cells. (A) GnRH-II increased MMP-2 protein expression in
endometrial cancer cells. (B) Conditioned medium from the treated cells was also collected and analyzed for MMP activity with gelatin
zymography. Arrows, gelatinase activities corresponding to pro-MMP-2, and active-MMP-2. Lane 1, a human MMP-2 standard was used as a
positive control. (C) The cells were pretreated with MMP-2 inhibitor. Pretreated cells were collected for the migration assay through uncoated
filter (left) and the invasion assay through Matrigel (right) in the presence or absence of GnRH-II. The results are expressed as the mean ± SEM of
three independent experiments. (*p<0.05, versus control; #p<0.05, versus GnRH-II).
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effects of GnRH-II in endometrial cancer.
Cancer cell metastasis is a complex process that in-
volves proteolysis, increased cell motility, and decreased
cell adhesion. MMP-2 has been suggested to play a crit-
ical role in cancer metastasis, and the up-regulation of
MMP-2 is associated with increased invasion and a poor
prognosis in cancer [35-38]. In addition to theirenzymatic activities, MMPs can also promote cancer cell
migration by influencing cytoskeletal organization through
their association with different families of adhesion recep-
tors [39]. In the present study, we demonstrated that
GnRH-II promotes the cell migration and invasion of
endometrial cancer cells through the increased expression
and proteolytic activity of MMP-2, which specifically
degrades the basement membrane. Pretreatment with
Wu et al. BMC Cancer 2013, 13:300 Page 9 of 11
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MMP-2 induced by GnRH-II, suggesting that the ERK1/2
and JNK signaling pathways may play an important role in
regulating MMP-2 expression. Taken together with the
previous results, the cell migration and invasion in endo-
metrial cancer is regulated by the activation of the ERK1/2
and JNK signaling pathways by GnRH-II and is accom-
panied by the induction of MMP-2. This is one of the
novel findings in the present study. In aggregate, our data
demonstrate that MMP-2 is closely associated with the
pathways of the MAPKs involved in the GnRH-II-induced
cell migration and invasion of endometrial cancer cells.
Targeting MMP-2 with an MMP-2 inhibitor blocked the
GnRH-II-induced cell migration and invasion, indicating
that the effects of GnRH-II in endometrial cancer cells are
strongly correlated with MMP-2 expression.
Conclusions
In conclusion, our findings suggest that the potential
role of GnRH-II in promoting the cell migration and
invasion of endometrial cancer is through the binding of
GnRH-I receptors, the activation of the ERK1/2 and
JNK pathways, and the subsequent induction of the
metastasis-related proteinase MMP-2 activity. This
information provides a mechanistic rationale for the
observed GnRH-I receptor expression in endometrial
cancer. Our findings provide a new insight regarding the
mechanism of GnRH-II-induced cell motility in endo-
metrial cancer and suggest the possibility of exploring
GnRH-II as a potential therapeutic molecular target for
the treatment of human endometrial cancer.
Methods
Cell lines and cell culture
The human endometrial cancer cell lines Ishikawa and
ECC-1 were utilized in this study. The human endomet-
rial cancer cell line Ishikawa is a well-differentiated
endometrial adenocarcinoma cell line [40]. The ECC-1
cell line, derived from a well-differentiated adenocarcin-
oma of the endometrium [41], was obtained from the
American Type Culture Collection (US). The cells were
cultured in Dulbecco’s minimum essential medium
(DMEM) with 10% fetal bovine serum (FBS; Hyclone
Laboratories Inc., Logan, UT), 100 U/ml penicillin, and
100 μg/ml streptomycin and incubated at 37°C in a
humidified incubator with 5% CO2. The cells were grown
to 80% confluence and transferred to serum-free medium
for 24 h prior to the treatment with the GnRH-II agonist.
Reagents
The GnRH-II agonist (D-Arg6, AzaGly10-GnRH II), a
synthetic decapeptide, was purchased from Bachem (San
Carlos, CA). The MAPK/extracellular signal-regulated
protein kinase (ERK) kinase (MEK) inhibitor U0126, theJNK inhibitor SP600125, and the MMP-2 inhibitor OA-
Hy were purchased from Calbiochem (San Diego, CA).
Immunoblot analysis
The cells were lysed in buffer containing 20 mM Tris,
pH 7.4, 2 mM EGTA, 2 mM Na2VO3, 2 mM Na4P2O7,
2% Triton X-100, 2% SDS, 1 μM aprotinin, 1 μM
leupeptin and 1 mM PMSF. The protein concentration
was determined with a protein assay kit using BSA stan-
dards according to the manufacturer's instructions (Bio-
Rad Laboratories, Hercules, CA). Equal amounts of cell
lysate were separated by SDS polyacrylamide gel electro-
phoresis (PAGE) and transferred to a nitrocellulose mem-
brane (Hybond-C, Amersham Pharmacia Biotech Inc.,
Oakville, ON). Following blocking with Tris-buffered
saline (TBS) containing 5% non-fat dry milk for 1 h, the
membranes were incubated overnight at 4°C with anti-
GnRH-I receptor (Neomarker, Fremont, CA), anti-
phospho-ERK1/2 (Cell signaling), anti-ERK1/2 (Cell
signaling), anti-phospho-JNK (Cell signaling), anti-JNK
(Cell signaling), or anti-MMP-2 (Calbiochem, San Diego,
CA) antibody followed by incubation with HRP-conjugated
secondary antibody. The immunoreactive bands were
detected with an enhanced chemiluminescence (ECL) kit.
The membrane was then stripped with stripping buffer
(62.5 mM Tris, 10 mM DTT, and 2% SDS, pH 6.7) at 50°C
for 30 min and re-probed with anti-β-actin antibody (Santa
Cruz) as a loading control.
Immunohistochemistry (IHC)
To determine the expression of the GnRH-I receptor
protein in human endometrial cancer, IHC was per-
formed on sections of human endometrial cancer tissue
using previously reported procedures [42]. The involve-
ment of human subjects in this study was approved by
the Institutional Review Board of Chang Gung Memorial
Hospital (CGMH-IRB numbers 101-2187B and 100-
3879C). Four-micrometer-thick formalin-fixed, paraffin-
embedded (FFPE) tissue sections were deparaffinized in
xylene and rehydrated with a graded series of ethanol so-
lutions. The sections were then stained with an anti-
human GnRH-I receptor polyclonal antibody (Neomarker;
1:100) using an automated IHC stainer with the Ventana
Basic DAB Detection kit (Tucson, AZ) according to the
manufacturer’s protocol. Counterstaining was performed
with hematoxylin. Sections were stained without the
GnRH-I receptor antibody as a negative control in the
third of three columns depicting the human endometrial
cancer tissue sections.
Small interfering RNA transfection
siGENOME ON-TARGETplus SMARTpool human GnRH-
I receptor siRNA and siCONTROL NON-TARGETING
pool siRNA were purchased from Dharmacon. The cells
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RNAiMAX. After a 24 h transfection, the medium was
removed and changed to fresh serum-free medium. To
examine the siRNA transfection, cells were transfected with
100 nM si-GLO (Dharmacon) for 24 hr. The transfection
efficiency was examined by fluorescent microscopy.
Invasion and migration assays
Migration and invasion assays were performed in Boy-
den chambers with minor modifications. Cell culture
inserts (24-well, pore size 8 μm; BD Biosciences, Missis-
sauga, ON) were seeded with 1x105 cells in 250 μL of
medium with 0.1% FBS. Un-coated inserts were used for
migration assays whereas inserts pre-coated with growth
factor reduced Matrigel (40 μl, 1 mg/ml; BD Biosciences)
were used for invasion assays. Medium with 10% FBS
(750 μl) was added to the lower chamber and served as
a chemotactic agent. After 24 hr (migration) or 48 hr
(invasion) incubation, non-migrating/invading cells were
wiped from the upper side of the membrane and cells
on the lower side were fixed in cold methanol (−20°C)
and air dried. The cells that had not penetrated the filter
were removed by wiping, and the cells that had invaded
the lower surface of the filter were fixed with ice-cold
methanol and stained with 0.5% crystal violet.
Gelatin zymography
The activity of MMP-2 in the conditioned medium was
determined by gelatin zymography. The media were col-
lected and clarified by centrifugation to remove cells and
debris. The samples were loaded under non-reducing
conditions onto SDS-polyacrylamide gel polymerized
with 1 mg/mL gelatin. Following electrophoresis, the
gels were washed with 2.5% Triton X-100 to remove
SDS and then incubated in a developing buffer overnight
at 37°C. The gels were stained with 0.25% Coomassie
Brilliant Blue R-250 and destained in the same solution
without dye. The gelatinase activity was visualized as
clear bands against the blue-stained gelatin background.
The molecular sizes were determined from mobility
using gelatin zymography standards.
Statistical analysis
The results are shown as the means ± SEM. Statistical
evaluation was conducted with the t-test for paired data.
Multiple comparisons were first analyzed by one-way
ANOVA, followed by Tukey’s multiple comparison test.
A significant difference was defined as p<0.05.
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